⌕
Dyne Therapeutics · DYN · Nasdaq
Tenet 52 · Mixed
Compare
$16.02−4.07%At closeTenet 52 · Mixed
$16.02−0.68 (−4.07%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Dyne Therapeutics (DYN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+152.4%) and Capex step-up ($20.7M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼40.6%
−446.2
FY21→FY25CAGR —
Free cash flow ($M)▼43.8%
−423.9
capex stepped upCAGR —
Diluted EPS▼3.0%
−3.47
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+152.4%

50.9mn → 128.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$20.7M

▲772% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−398.3R&D−69.9SG&A−468.2Op income22.0Tax & other−446.2Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7066, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
510,233.0398,333.0281,406.0210,762.0142,760.0121,308.0▲41.6%+34.6%
Selling, general & admin
109,907.069,851.062,480.031,400.028,202.028,717.0▲11.8%+24.9%
Total operating expenses
620,140.0468,184.0343,886.0242,162.0170,962.0150,025.0▲36.1%+32.9%
Operating incomefeeds ROC rank
−620,140.0−468,184.0−343,886.0−242,162.0−170,962.0−150,025.0▼36.1%—
Other income, net
15,223.021,970.026,468.06,225.02,863.0734.0——
Pretax income
−604,917.0−446,214.0−317,418.0−235,937.0−168,099.0−149,291.0▼40.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−604,917.0−446,214.0−317,418.0−235,937.0−168,099.0−149,291.0▼40.6%—
Per share
Diluted EPSbuyback-sensitive
−3.56−3.47−3.37−3.95−3.23−2.93▼3.0%—
Diluted shares (mn)
181.77128.4494.1459.6851.9850.90▲36.4%+26.0%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.